Clinical Study Results
The tables below show the different treatments in each part of the study.
Part A treatments
Group Number of participants
number out of 119 participants Treatment
• 125 mg adavosertib twice daily for 6 days per cycle
1 3 participants
• 100 mg olaparib twice daily for 14 days per cycle
• 150 mg adavosertib twice daily for 6 days per cycle
2 3 participants
• 100 mg olaparib twice daily for 14 days per cycle
• 175 mg adavosertib twice daily for 6 days per cycle
3 4 participants
• 100 mg olaparib twice daily for 14 days per cycle
• 150 mg adavosertib twice daily for 6 days per cycle
4 7 participants
• 200 mg olaparib twice daily for 14 days per cycle
• 175 mg adavosertib twice daily for 6 days per cycle
5 7 participants
• 200 mg olaparib twice daily for 14 days per cycle
• 175 mg adavosertib twice daily for 6 days per cycle
6 14 participants
• 200 mg olaparib twice daily for 21 days per cycle
• 175 mg adavosertib twice daily for 9 days per cycle
7 14 participants
• 200 mg olaparib twice daily for 21 days per cycle
• 175 mg adavosertib twice daily for 6 days per cycle
8 5 participants
• 300 mg olaparib twice daily for 14 days per cycle
• 250 mg adavosertib once daily for 10 days per cycle
9 8 participants
• 200 mg olaparib twice daily for 21 days per cycle
• 200 mg adavosertib once daily for 10 days per cycle
10 7 participants
• 200 mg olaparib twice daily for 21 days per cycle
• 250 mg adavosertib once daily for 6 days per cycle
11 16 participants
• 200 mg olaparib twice daily for 21 days per cycle
• 250 mg adavosertib once daily for 9 days per cycle
12 4 participants
• 200 mg olaparib twice daily for 21 days per cycle
• 300 mg adavosertib once daily for 6 days per cycle
13 3 participants
• 200 mg olaparib twice daily for 21 days per cycle
• 200 mg adavosertib once daily for 6 days per cycle
14 13 participants
• 200 mg olaparib twice daily for 21 days per cycle
• 200 mg adavosertib once daily for 6 days per cycle
15 11 participants
• 300 mg olaparib twice daily for 21 days per cycle
Part B Treatments
Group Number of participants
number out of 9 participants Treatment
• 200 mg adavosertib once daily for 6 days per cycle
16 9 participants
• 200 mg olaparib twice daily for 21 days per cycle
The study drug doses and schedule used in Group 14 in Part A were the same
doses and schedule used in Group 16 in Part B.
5